VALERIE DENNIS: Open Payments
NPI 1679148241 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,496 in 25 payments from 9 companies in 2025. Trend: 2023 $65 · 2024 $255 · 2025 $2,496
Consulting: $1,542Food & beverage: $887Education: $68
| Company | Payments | Amount |
|---|---|---|
| Veloxis Pharmaceuticals, Inc. | 13 | $2,124 |
| Novartis Pharmaceuticals Corporation | 3 | $92 |
| Endologix LLC | 1 | $68 |
| GlaxoSmithKline, LLC. | 3 | $63 |
| Mallinckrodt Hospital Products Inc. | 1 | $39 |
| Apellis Pharmaceuticals, Inc. | 1 | $34 |
| Travere Therapeutics, Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $24 |
Products named: ENVARSUS, Fabhalta, ENDOCROSS Device, BENLYSTA, TERLIVAZ, LIVTENCITY, XIFAXAN.
Industry payments across TX — which companies pay providers there.
